Advanced in Breast Cancer

Dr. Jonathan R. Whisenant

Oncology
Intermountain Health
Utah Cancer Specialists - Murray
5131 South Cottonwood Street, Suite L2, 
Murray, UT 
Accepting New Patients
Offers Telehealth
28 Years of Experience
Advanced in Breast Cancer
Intermountain Health
Utah Cancer Specialists - Murray
5131 South Cottonwood Street, Suite L2, 
Murray, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Whisenant is an Oncologist in Murray, Utah. Dr. Whisenant has been practicing medicine for over 28 years and is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gastrointestinal Stromal Tumor, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Whisenant is currently accepting new patients.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Breast Cancer.

Graduate Institution
University Of Colorado Hospital, 1998
Residency
University of Colorado Hospital
Specialties
Oncology
Licenses
Internal Medicine in UT
Board Certifications
American Board Of Internal Medicine
Fellowships
University of California San Francisco
Hospital Affiliations
Riverton Hospital
Alta View Hospital
Intermountain Medical Center
Utah Valley Hospital
LDS Hospital
American Fork Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Utah Cancer Specialists - Murray
5131 South Cottonwood Street, Suite L2, Murray, UT 84107
Call: 801-263-3416

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Drug, Biological
Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Study Phase: Phase 1
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: December 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

20 Total Publications

Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Journal: Nature medicine
Published: April 25, 2025
View All 20 Publications
Similar Doctors
Elite in Breast Cancer
Dr. Saundra S. Buys
Oncology | Hematology
Elite in Breast Cancer
Dr. Saundra S. Buys
Oncology | Hematology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (8.4 miles away)
801-581-8793
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Saundra Buys is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Buys is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Ovarian Cancer, Muscle Invasive Bladder Cancer, and Salpingo-Oophorectomy. Dr. Buys is currently accepting new patients.

Distinguished in Breast Cancer
Dr. Jairam Krishnamurthy
Oncology | Hematology
Distinguished in Breast Cancer
Dr. Jairam Krishnamurthy
Oncology | Hematology

University Of Utah Adult Services

50 N Medical Dr, 
Salt Lake City, UT 
 (8.2 miles away)
801-585-6387
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

Jairam Krishnamurthy is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Krishnamurthy is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Liver Embolization. Dr. Krishnamurthy is currently accepting new patients.

Christos Vaklavas
Distinguished in Breast Cancer
Dr. Christos Vaklavas
Hematology Oncology | Hematology | Oncology
Distinguished in Breast Cancer
Dr. Christos Vaklavas
Hematology Oncology | Hematology | Oncology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (8.4 miles away)
801-581-8793
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Christos Vaklavas is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Vaklavas is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Advanced Bronchoscopy. Dr. Vaklavas is currently accepting new patients.

VIEW MORE BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Whisenant's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Whisenant is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Whisenant is
      Distinguished
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Colorectal Cancer
      Dr. Whisenant is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Whisenant is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Gastrointestinal Stromal Tumor
      Dr. Whisenant is
      Distinguished
      . Learn about Gastrointestinal Stromal Tumor.
      See more Gastrointestinal Stromal Tumor experts
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Whisenant is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Whisenant is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Ampullary Cancer
      Dr. Whisenant is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Angiosarcoma
      Dr. Whisenant is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Appendix Cancer
      Dr. Whisenant is
      Advanced
      . Learn about Appendix Cancer.
      See more Appendix Cancer experts
    • Bone Tumor
      Dr. Whisenant is
      Advanced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    View All 39 Advanced Conditions
    • Experienced
    • Adrenal Cancer
      Dr. Whisenant is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adrenocortical Carcinoma
      Dr. Whisenant is
      Experienced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Whisenant is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alveolar Soft Part Sarcoma
      Dr. Whisenant is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Angiosarcoma of the Scalp
      Dr. Whisenant is
      Experienced
      . Learn about Angiosarcoma of the Scalp.
      See more Angiosarcoma of the Scalp experts
    • B-Cell Lymphoma
      Dr. Whisenant is
      Experienced
      . Learn about B-Cell Lymphoma.
      See more B-Cell Lymphoma experts
    View All 96 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.